Advances in Therapy

, Volume 22, Issue 1, pp 49–55

Longitudinal assessment of the dose consistency of botulinum toxin type a (BOTOX®) for cervical dystonia

  • Allison Brashear
  • Patrick Hogan
  • Maureen Wooten-Watts
  • Albert Marchetti
  • Raf Magar
  • John Martin


Botulinum toxin type A (BoNT/A) is the principal therapy for patients with cervical dystonia. Repeated treatments over many years are required in most cases. This retrospective review evaluates the dose of BoNT/A used to treat cervical dystonia and the interval between treatments during a 2-year observation period. Outcomes data were abstracted from the medical records of 172 patients at 3 different sites who had received BoNT/A between January and December 1998. A total of 1059 treatments were assessed. Mean per-treatment doses throughout the 2-year study ranged from 241.80 to 254.07 units. The mean interval between treatments was 108.48 days during the first year of observation and 114.14 days during the second year. These findings indicate that doses of and intervals between BoNT/A treatments for cervical dystonia were consistent throughout 2 years of observation.


botulinum toxin type A cervical dystonia spasmodic torticollis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jahanshahi M, Marion M.H, Marsden C.D. Natural history of adult-onset idiopathic torticollis.Arch Neurol. 1990;47:548–552.PubMedGoogle Scholar
  2. 2.
    Dauer WT, Burke RE, Greene P, Fahn S. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia.Brain. 1998;121(pt 4):547–560.PubMedCrossRefGoogle Scholar
  3. 3.
    Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections.Neurology. 1995;45:1743–1746.PubMedGoogle Scholar
  4. 4.
    Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis.Lancet. 1986;2(8501):245–247.PubMedCrossRefGoogle Scholar
  5. 5.
    Brans JW, Lindeboom R, Aramideh M, Speelman JD. Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia.Neurology. 1998;50:1461–1463.PubMedGoogle Scholar
  6. 6.
    Naumann M, Yakovleff A, Durif F. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia.J Neurol. 2002;249:57–63.PubMedCrossRefGoogle Scholar
  7. 7.
    Hilker R, Schischniaschvili M, Ghaemi M, Jacobs A, Rudolf J. Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia.J Neurol Neurosurg Psychiatry. 2001;71:193–199.PubMedCrossRefGoogle Scholar
  8. 8.
    Brashear A, Watts MW, Marchetti A, Magar R, Lau H, Wang L. Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review.Clin Ther. 2000; 22:1516–1524.PubMedCrossRefGoogle Scholar
  9. 9.
    Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up.Neurology. 1999;53:2102–2107.PubMedGoogle Scholar
  10. 10.
    Mehta RP, Goldman SN, Orloff LA. Long-term therapy for spasmodic dysphonia: acoustic and aerodynamic outcomes.Arch Otolaryngol Head Neck Surg. 2001;127:393–399.PubMedGoogle Scholar
  11. 11.
    Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.Mov Disord. 2002;17:1288–1293.PubMedCrossRefGoogle Scholar
  12. 12.
    Defazio G, Abbruzzese G, Girlanda P, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study.Arch Neurol. 2002;59:418–420.PubMedCrossRefGoogle Scholar
  13. 13.
    Jankovic J, Schwartz KS. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia.Neurology. 1993;43:834–836.PubMedGoogle Scholar
  14. 14.
    Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis.Mov Disord. 1994;9:213–217.PubMedCrossRefGoogle Scholar
  15. 15.
    BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex prescribing information. Allergan, Inc, Irvine, Calif, 2000.Google Scholar
  16. 16.
    Jankovic J, Ahsan J, Vuong KD. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia.Neurology. 2003;60:1186–1188.PubMedGoogle Scholar
  17. 17.
    Dressler D, Munchau A, Bhatia KP, Quinn NP, Bigalke H. Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses?Eur Neurol. 2002;47: 118–121.PubMedCrossRefGoogle Scholar
  18. 18.
    Dutton JJ, Buckley EG. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm.Ophthalmology. 1988;95:1529–1534.PubMedGoogle Scholar
  19. 19.
    Dodel RC, Kirchner A, Koehne-Volland R, et al. Costs of treating dystonias and hemifacial spasm with botulinum toxin A.Pharmacoeconomics. 1997;12:695–706.PubMedCrossRefGoogle Scholar
  20. 20.
    Hauser RA, Comella C, Brashear A, et al. A randomized, multicenter, double-blind, placebo-controlled study of original Botox (botulinum toxin type A) purified neurotoxin complex for the treatment of cervical dystonia [abstract].Mov Disord. 2000;15(suppl 2):30–31.Google Scholar

Copyright information

© Health Communications Inc 2005

Authors and Affiliations

  • Allison Brashear
    • 1
  • Patrick Hogan
    • 2
  • Maureen Wooten-Watts
    • 3
  • Albert Marchetti
    • 4
  • Raf Magar
    • 4
  • John Martin
    • 4
  1. 1.Department of NeurologyIndiana University Medical CenterIndianapolis
  2. 2.Puget Sound Movement Disorder and Headache ClinicTacoma
  3. 3.Neurology Specialists of DallasDallas
  4. 4.Thomson Health Economics ResearchSecaucus

Personalised recommendations